ResearcherShihezi UniversityActive in the last 2 years

Zhenli Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-1809-186X; OpenAlex author ID A5100950974. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 2 papers

Papers 2

Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance. Co-author DOI 10.1007/s10555-023-10125-y ↗
Transcriptomics and molecular docking reveal the potential mechanism of lycorine against pancreatic cancer. First author DOI 10.1016/j.phymed.2023.155128 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Milad Ashrafizadeh · 1 shared paper, 2024 · strength 0.26
- Paper Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiven… DOI 10.1007/s10555-023-10125-y ↗
Xianbin Zhang · 1 shared paper, 2024 · strength 0.26
- Paper Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiven… DOI 10.1007/s10555-023-10125-y ↗
Xin Zhou · 1 shared paper, 2024 · strength 0.23
- Paper Transcriptomics and molecular docking reveal the potential mechanism of lycorine against pancreatic cancer. DOI 10.1016/j.phymed.2023.155128 ↗
Ketao Ma · 1 shared paper, 2024 · strength 0.23
- Paper Transcriptomics and molecular docking reveal the potential mechanism of lycorine against pancreatic cancer. DOI 10.1016/j.phymed.2023.155128 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.